Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-MTN@IG-P
- Development stage
- Preclinical
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous, Intrathecal, Topical, Transdermal, Intranasal, Rectal, Ophthalmic, Parenteral, Implant
01
Overview
**S-MTN@IG-P** is an experimental, light-responsive silica-based mesoporous titania nanoplatform developed for chemo-photothermal treatment of colon cancer. It encapsulates **imatinib** within silica-based mesoporous titania nanoparticles and incorporates graphene oxide modified with a stealth polymer coating. Under near-infrared irradiation, the graphene oxide component generates heat and reactive oxygen species, while acidic tumor-like conditions and light promote imatinib release. In preclinical HCT-116 and HT-29 colon cancer models and tumor-bearing animals, the formulation showed tumor accumulation and enhanced antitumor activity without reported biocompatibility concerns.
- Other names
- S-MTN@IG-P
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on S-MTN@IG-P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-MTN@IG-P.